North America Bioequivalence Studies Market Size & Outlook
North America bioequivalence studies market, 2018-2030 (US$M)
Related Markets
North America bioequivalence studies market highlights
- The North America bioequivalence studies market generated a revenue of USD 311.8 million in 2023.
- The market is expected to grow at a CAGR of 8.3% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating molecule type in 2023.
- Large Molecule is the most lucrative molecule type segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 311.8 million |
| Market revenue in 2030 | USD 545.8 million |
| Growth rate | 8.3% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, Icon PLC, Charles River Laboratories International Inc, Labcorp Drug Development, Kymos Pharma Services, Spectris PLC |
Other key industry trends
- In terms of revenue, North America region accounted for 42.9% of the global bioequivalence studies market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 279.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Bioequivalence Studies Market Scope
Bioequivalence Studies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America bioequivalence studies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to bioequivalence studies market will help companies and investors design strategic landscapes.
Small molecule was the largest segment with a revenue share of 60.42% in 2023. Horizon Databook has segmented the North America bioequivalence studies market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
- North America Bioequivalence Studies Molecule Type Outlook (Revenue, USD Million, 2018-2030)
- Small Molecule
- Large Molecule
- North America Bioequivalence Studies Dosage Form Outlook (Revenue, USD Million, 2018-2030)
- Solid Oral Dosage
- Parenteral Formulations
- Topical Products
- Others
- North America Bioequivalence Studies Therapeutic Area Outlook (Revenue, USD Million, 2018-2030)
- Oncology
- Neurology
- Metabolic Disorders
- Hematology
- Immunology
- Others
Reasons to subscribe to North America bioequivalence studies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America bioequivalence studies market databook
-
Our clientele includes a mix of bioequivalence studies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America bioequivalence studies market, including forecasts for subscribers. This continent databook contains high-level insights into North America bioequivalence studies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America bioequivalence studies market report size, by country, 2018-2030 (US$M)
North America Bioequivalence Studies Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
